Dark

Check out our API

CRTX
Cortexyme, Inc. Common Stock
stock NASDAQ

Inactive

Jul 29, 2022

1.95USD+2.632%(+0.05)272,208

Pre-market

0.00USD-100.000%(-1.90)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

07:59PM EST Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (Cortexyme or the Company) (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Jan 28, 2022

10:17AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 28, 2022 Benzinga

06:08AM EST Canaccord Genuity Downgrades Cortexyme to Hold Benzinga

Jan 27, 2022

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2022 Benzinga

06:24AM EST JMP Securities Downgrades Cortexyme to Market Perform Benzinga

05:01AM EST 41 Biggest Movers From Yesterday Benzinga

Jan 26, 2022

02:33PM EST Mid-Afternoon Market Update: Nasdaq Surges Over 300 Points; Fed Leaves Rates Unchanged Benzinga

12:35PM EST Mid-Afternoon Market Update: Nasdaq Surges Over 300 Points; Cortexyme Shares Plummet Benzinga

12:12PM EST Mid-Day Market Update: Gold Down 1%; Corning Shares Gain On Upbeat Earnings Benzinga

10:28AM EST Mid-Morning Market Update: Markets Open Higher; AT&T Earnings Top Expectations Benzinga

08:10AM EST Cortexyme Announces Clinical Hold On Atuzaginstat's Investigational New Drug Application Benzinga

Jan 10, 2022

02:11PM EST Cortexyme has received a Notice of Allowance for its US patent application 16/899,376 titled "KETONE INHIBITORS OF LYSINE GINGIPAIN Benzinga

Nov 11, 2021

11:30AM EST Cortexyme Reports Its Atuzaginstat Slowed Cognitive Decline In Participants With Alzheimer's, P. Gingivalis Infection In Phase 2/3 Trial Benzinga

08:03AM EST The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 4, 2021

09:11AM EDT Cortexyme To Present Additional Top-Line GAIN Trial Results, Analysis At CTAD 2021 On Nov. 11th Benzinga

Nov 3, 2021

12:19PM EDT This Is What Whales Are Betting On Cortexyme Benzinga

Nov 1, 2021

03:23PM EDT Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. (Cortexyme or the Company) (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 27, 2021

02:40PM EDT Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge Benzinga

01:55PM EDT Why Cortexyme Shares Are Falling Benzinga

12:15PM EDT Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher Benzinga

10:21AM EDT Mid-Morning Market Update: Markets Rise; Coca-Cola Tops Q3 Views Benzinga

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2021 Benzinga

07:37AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:34AM EDT B of A Securities Downgrades Cortexyme to Underperform Benzinga

07:16AM EDT HC Wainwright & Co. Maintains Buy on Cortexyme, Lowers Price Target to $30 Benzinga

06:13AM EDT The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 05.55 A.M. EDT). RTTNews

Oct 26, 2021

04:02PM EDT Cortexyme Reports GAIN Trial Data; Co Says Data Demonstrated Relationship Between Reduction Of P. gingivalis Infection And Slowing Of Alzheimer's Disease Progression Benzinga

04:01PM EDT Cortexyme Shares Halted On Code News Pending Benzinga

Oct 14, 2021

09:12AM EDT Clarus Therapeutics To Present New Real-World Experience Data For JATENZ At 22nd Annual Fall Scientific Meeting Of SMSNA Benzinga

Sep 27, 2021

08:02AM EDT Cortexyme To Present Results From GAIN Trial Phase 2/3 Study Of Atuzaginstat In Mild To Moderate Alzheimer's Disease At CTAD 2021 Nov. 9-12 Benzinga

Sep 16, 2021

09:01AM EDT Canaccord Genuity Maintains Buy on Cortexyme, Raises Price Target to $150 Benzinga

Sep 8, 2021

08:07AM EDT Cortexyme Expands Proprietary Development Pipeline With Initiation Of Phase 1 Clinical Trial Of COR588 Benzinga

Aug 26, 2021

07:55AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

06:31AM EDT HC Wainwright & Co. Maintains Buy on Cortexyme, Raises Price Target to $200 Benzinga

Aug 25, 2021

08:04AM EDT Cortexyme Highlights Presentation Of Data Demonstrating Evidence Of P. Gingivalis Infection At Annual Biomarkers For Alzheimer's Disease Summit Benzinga

Aug 16, 2021

04:12PM EDT Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case Benzinga

Aug 15, 2021

12:16PM EDT The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

11:06AM EDT The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 9, 2021

02:35PM EDT Mid-Afternoon Market Update: Aterian Falls After Q2 Results; Select Interior Concepts Shares Spike Higher Benzinga

12:22PM EDT Mid-Day Market Update: Crude Oil Down 2.5%; Golden Nugget Online Gaming Shares Jump Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Jul 26, 2021

09:07AM EDT Cortexyme Highlights Presentation Of Alzheimers Data At AAIC 2021 Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 23, 2021

09:50AM EDT Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate Benzinga

08:03AM EDT Cortexyme Selects 3CLpro Inhibitor COR803 For Treatment Of Coronavirus Infection Benzinga

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

May 10, 2021

08:56AM EDT Cortexyme Q1 EPS $(0.78) Down From $(0.61) YoY Benzinga

08:00AM EDT Cortexyme Provides Business Update and Reports First Quarter 2021 Results Business Wire

May 4, 2021

08:00AM EDT Cortexyme to Present at the BofA Securities 2021 Healthcare Conference on May 11, 2021 Business Wire

Mar 28, 2021

08:15AM EDT The Past Week's Notable Insider Buys: Babcock & Wilcox, Designer Brands And More Benzinga

Mar 25, 2021

08:00AM EDT Cortexyme to Present at the Stifel 3rd Annual CNS Day on April 1, 2021 Business Wire

Mar 10, 2021

08:00AM EST Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021 Business Wire

Mar 8, 2021

08:51AM EST Cortexyme Announces Partnership With Parkinson Study Group RTTNews

08:46AM EST Cortexyme Announces Partnership with Parkinson Study Group and Upcoming Alzheimer's Disease Data Presentation Business Wire

08:04AM EST Cortexyme Partners With Parkinson Study Group To Form Advisory Board Benzinga

Feb 17, 2021

10:12AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021 Benzinga

06:43AM EST Jefferies Downgrades Cortexyme to Hold, Lowers Price Target to $34 Benzinga

Feb 16, 2021

12:46PM EST 43 Stocks Moving In Tuesday's Mid-Day Session Benzinga

08:52AM EST Cortexyme Stops Enrollment In Mid-Stage Atuzaginstat Study In Alzheimer's Disease Benzinga

Feb 15, 2021

10:41PM EST Cortexyme Inc. (CRTX), in an update on development program for Atuzaginstat in Alzheimer's Disease, said that the U.S. Food and Drug Administration has placed a partial clinical hold on atuzaginstat (COR388) that will impact the open-label extension or OLE phase of the company's ongoing Phase 2/3 study, the GAIN Trial. RTTNews

09:30PM EST Cortexyme Says FDA Places Partial Clinical Hold On Atuzaginstat In Alzheimer's Disease RTTNews

09:13PM EST Cortexyme Provides Regulatory Update on Development Program for Atuzaginstat in Alzheimer's Disease Business Wire

Feb 10, 2021

04:06PM EST Cortexyme Announces Leadership Appointments to Support Advancement of Atuzaginstat and Pipeline Expansion Business Wire

Jan 26, 2021

08:00AM EST Cortexyme Announces Pipeline Update and Anticipated 2021 Milestones Business Wire

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 11, 2020

06:04AM EST Citigroup Initiates Coverage On Cortexyme with Sell Rating, Announces Price Target of $20 Benzinga

Dec 7, 2020

10:08AM EST B of A Securities Upgrades Cortexyme to Buy Benzinga

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

07:07AM EST Cortexyme: Phase 2/3 GAIN Trial Of Atuzaginstat In Patients With Alzheimer's Disease Advances Past Interim Analysis RTTNews

07:01AM EST Cortexyme Reports Its Phase 2/3 GAIN Trial Of COR388 In Patients With Alzheimer's Disease Successfully Advances Past Interim Analysis Benzinga

07:00AM EST Cortexyme's Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer's Disease Successfully Advances Past Interim Analysis Business Wire

Nov 12, 2020

04:35PM EST Cortexyme Q3 EPS $(0.73) Down From $(0.37) YoY Benzinga

04:30PM EST Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update Business Wire

Nov 5, 2020

08:23AM EST Cortexyme Presents At Update And Baseline Data From Phase 2/3 GAIN Trial Of Atuzaginstat At CTAD 2020 Benzinga

08:00AM EST Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer's Disease Conference Business Wire

Oct 19, 2020

08:00AM EDT Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences Business Wire

Sep 24, 2020

08:09AM EDT Cortexyme Announces GAIN Trial Of Atuzaginstat In Alzheimer's Disease Has Exceeded Study Enrollment Target Of 570 Patients Benzinga

Sep 9, 2020

08:00AM EDT Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 Business Wire

Aug 27, 2020

08:12AM EDT Cortexyme Announces Issuance Of Composition Of Matter Patent For Atuzaginstat By The US Patent And Trademark Office Benzinga

Aug 17, 2020

08:18AM EDT Cortexyme Q2 EPS $(0.60) Down From $(0.57) YoY Benzinga

08:00AM EDT Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business Update Business Wire

Aug 14, 2020

08:04AM EDT Cortexyme Announces GAIN Trial Of Atuzaginstat In Alzheimer's Disease Has Reached Enrollment Milestone Of 500 Patients Benzinga

Aug 6, 2020

04:05PM EDT Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020 Business Wire

Jul 29, 2020

08:00AM EDT Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020 Business Wire

Jul 28, 2020

06:09PM EDT Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases Business Wire

Jul 22, 2020

08:09AM EDT Cortexyme Announces Upcoming Data Presentations At Alzheimer's Association International Conference 2020 RTTNews

08:08AM EDT Cortexyme Announces Upcoming Data Presentations At The Alzheimer's Association International Conference 2020 Benzinga

Share